表紙
市場調查報告書

次世代定序的全球市場:產品 & 服務、用途、技術、18個國家的資料 - 分析與預測 (2019-2024年)

Global Next-Generation Sequencing Market: Focus on Products and Services, Applications, Technology, 18 Countries Data, Industry Insights, and Competitive Landscape - Analysis and Forecast, 2019-2024

出版商 BIS Research Inc. 商品編碼 822862
出版日期 內容資訊 英文 287 Pages
商品交期: 最快1-2個工作天內
價格
次世代定序的全球市場:產品 & 服務、用途、技術、18個國家的資料 - 分析與預測 (2019-2024年) Global Next-Generation Sequencing Market: Focus on Products and Services, Applications, Technology, 18 Countries Data, Industry Insights, and Competitive Landscape - Analysis and Forecast, 2019-2024
出版日期: 2019年03月31日內容資訊: 英文 287 Pages
簡介

全球次世代定序市場預測在2024年前達到99億1,000萬美元的規模。

本報告提供全球次世代定序市場調查,市場概要,市場成長的各種影響因素及市場機會分析,各市場區隔、地區/主要國家等各種區分的趨勢與市場規模的變化與預測,競爭環境,及主要企業的簡介等系統性資訊。

摘要整理

第1章 市場概要

第2章 市場動態

  • 影響分析
  • 市場成長的促進因素
  • 市場成長的阻礙因素
  • 市場機會

第3章競爭考察形勢

  • 主要策略、發展
  • 市場佔有率分析
  • 成長佔有率分析
  • 價值鏈分析
  • 每基因100美元:預測的醫學、個體化醫療的時代
  • 產業的魅力

第4章 產業分析

  • NGS市場新興企業、主要投資者
  • 法律上的必要條件、規定
  • 次世代定序市場上服務供應商所扮演的角色

第5章 全球NGS市場:各產品類型

  • 設備
  • 套件、消耗品
  • 軟體

第6章 全球NGS市場:各技術

  • 可逆終止子定序
  • Ion Torrent半導體定序
  • 單分子即時定序 (SMRT)
  • 奈米孔定序技術
  • 其他

第7章 全球NGS市場:各用途

  • 醫藥品
  • 診斷
  • 農業、動物研究
  • 鑑識
  • 其他

第8章 全球NGS市場:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他 (RoW)

第9章 企業簡介

  • 概要
  • 10x Genomics
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc
  • BGI
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • New England Biolabs, Inc
  • NuGEN Technologies, Inc.
  • Oxford Nanopore Technologies Limited
  • Pacific Biosciences of California, Inc.
  • QIAGEN N.V.
  • PerkinElmer, Inc.
  • Thermo Fisher Scientific

第10章 調查範圍、調查手法

目錄
Product Code: BH039C

"Global Next-generation Sequencing Market is Projected to Reach $9.91 Billion by 2024"

The next-generation sequencing (NGS) industry is a multibillion market which consists of multitudinous companies involved in the manufacturing of instruments and kits and consumables and the development of software to bolster the NGS workflow. NGS has fundamentally changed the genomic research. It enables the scientist to sequence an entire genome, exome, or transcriptome by conducting experiments that were previously impossible. There were some limitations with traditional sequencing platforms. Platforms rely on the reads that are short and are less than 1Kb, further requiring scale up to millions of fragments that are sequenced in parallel.

Advancements in sequencing chemistry, molecular biology, and technical engineering over the years have profoundly increased the sequencing efficiency while decreasing the cost. Impressive progress in these fields have paved the way for the development of massively parallel, high-throughput sequencing technology, known as Next-Generation Sequencing (NGS).

The purpose of this study is to gain a holistic view of the NGS market in terms of various influencing factors, such as trends, technological advancements, role of service providers, and funding scenario in the market. The scope of this report constitutes of an in-depth study of the global next-generation sequencing market, including a thorough analysis of the products across different regions. The market has been segmented into 'technology', 'product', 'application' and 'geographical regions'. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global NGS market with the help of key factors driving the market, restraints, and challenges that can possibly inhibit the overall market growth and the current growth opportunities that are likely to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key ecosystem players and key strategies and developments taking place in this market. In addition, the report includes market dynamics (market drivers, opportunities, and challenges) and industry analysis.

The research study considers the market share analysis for a comprehensive understanding of the global NGS market and assesses the factors governing the same. Funding scenarios, Porter's Five Force analysis, opportunity matrix, detailed product mapping, pricing analysis, value chain analysis, supply chain of NGS kits and consumables, growth share analysis by products and sequencing instrument provider, and R&D analysis have been included in the report.

The market by region has been further sub-segmented into countries, and the key market trends, key players, and recent developments have been listed in each sub-segment. The answers to the following key questions can be derived from this report:

  • What are the major market drivers, challenges, and opportunities in the global NGS market?
  • How did the NGS market evolve and what is its scope in the future?
  • What was the market share of the leading segments and sub-segments of the global NGS market in 2018?
  • How is each segment of the global NGS market expected to grow during the forecast period, and how much revenue is expected to be generated by each of the segments by the end of 2024?
  • What are the influencing factors that may affect the market share of the key players?
  • What is the influential stake held by the sequencing technology providers in the global NGS market?
  • What is the growth potential of different sequencing technologies in the forecast period 2019-2024?
  • What is expected to be the impact of commercialization of the portable sequencers on global healthcare industry?
  • What are the required features for an instrument to make $100 per genome sequencing a reality?
  • What is industry's best value chain practice?
  • Which are the leading raw material providers to the players offering NGS kits and consumables?
  • What is the market dominance by key players in each region?
  • How is the industry expected to evolve during the forecast period 2019- 2024?
  • What are the key developmental strategies which are being implemented by the key players to stand out in this market?
  • Which are the key service providers of the NGS market?
  • What is the funding scenario for the emerging companies that are investing substantial amount into the development of propitious technologies or products for bringing forth the evolution of the NGS market?
  • How has the market been segmented on the basis of sequencing technology? Which NGS technology is being adopted extensively for undertaking the sequencing procedure?
  • What is the market share of the companies by different segments, namely products, technology, applications, and geography, along with the global share analysis of the market?

The key players which have been contributing significantly to the NGS market include: 10x Genomics, Agilent Technologies, Inc., bioMerieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, GenapSys, Inc., Illumina, Inc., New England Biolabs, Inc., NuGEN Technologies Inc., Oxford Nanopore Technologies Limited, Pacific Biosciences of California, Inc., PerkinElmer, Inc., QIAGEN, and Thermo Fisher Scientific, among others.

Executive Summary

In the past few years, genome of several species has been sequenced using the automated sanger sequencing. There have been limitations associated with the sanger sequencing, leading to the development of improved sequencing technologies that are capable of sequencing a large number of human genome and are also capable of addressing the problems that were initially hindering growth of the next-generation sequencing (NGS) market. Further, several research centres initiated the designing of the new sequencing technologies which would not require gels and would allow sequencing of a large number of samples in parallel. The three parallel technologies that were introduced in the early 21st century are Polonator, the Heliscope Single Molecule Sequencer Technology, and the Ion Semi-Conductor (Torrent Ion Sequencing). Since the introduction of these technologies, several attempts were made in the past to generate efficient sequencing technologies that would rely on single molecules, excluding the need for amplification steps. The two promising such technologies are Pacific Single molecule real time (SMRT) DNA sequencing and nanopore DNA sequencing. The advent of aforementioned technologies has unleased some novel methods which hold the potential to make the $100 genome dream a reality in the near future. These high-throughput sequencing methods have introduced new fields in the industry, which include analysis of RNA transcript, personal genomics, ChiP-Seq (Chromatin Immunoprecipitation sequencing), and ChiP-chip (Chromatin Immunoprecipitation coupled to DNA microarray), among others.

NGS in the clinical setting requires infrastructure, such as storage and computer capacity, and also the personnel expertise required to comprehensively analyse and interpret the subsequent data.

In addition, the volume of the data needs to be managed skilfully to properly extract the clinically important functions in a robust and clear interface.

The purpose of the study is to gain a holistic view of the next-generation sequencing market in terms of various influencing factors, such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the technologies allied with the next-generation sequencing market. The global next-generation sequencing market is segmented on the basis of four sections, namely product, technology, application and geography. The global market value was estimated using these four different approaches and was validated with one another. These segments are further segmented into several sub-segments to ease the market estimation and to gain an in-depth view of the market.

The global next-generation sequencing market was $4.93 billion in 2018 and is estimated to grow over $9.91 billion by 2024. The global next-generation sequencing market is expected to grow with a double-digit compound annual growth rate between the years 2019 and 2024. With substantial increase in the demand for genome mapping programs and diagnostics tests based on sequencing, the NGS market is expected to witness an impressive growth and promises to be a lucrative field for investment. In terms of products, the kits and consumables sub-segment dominated the global next-generation sequencing market in 2018. However, the software sub-segment is expected to witness the highest CAGR in the forecast period from 2019 to 2024.

The reversible terminator sequencing technology currently dominates the global NGS market. Nanopore technology is estimated to witness the highest CAGR in the forecast period.

And by application, presently, the pharmaceuticals field holds the largest share of the global next-generation sequencing market and is expected to grow at 13.22% CAGR in the forecast period from 2019 to 2024. However, with the growing demand for non-invasive diagnostic procedures, the diagnostic field is expected to witness an impressive CAGR in the forecast period from 2019 to 2024. The global next-generation sequencing market is segmented by geographical regions into North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World (RoW). North America is the leading contributor to the global next-generation sequencing market and contributed to 48% of the global market values in 2018. However, Asia-Pacific is expected to grow at a CAGR of 17.25% in the forecast period 2019-2024. Moreover, the Asia Pacific market contributed approximately 18.95% of the total global market value in 2018.

A paradigm shift in the dynamics market is expected in 2023 with the introduction of portable technologies in full scale. The leading players in the market are taking necessary steps to tackle the shift in the dynamics and sustain in the competition. The global next-generation sequencing market is majorly dominated by the U.S. players. Companies belonging to the U.S., such as Illumina, Inc., and Thermo Fisher Scientific, contributed to more than 70% of the market value in 2018. The key players which have significant contributions to the NGS market are 10x Genomics, Agilent Technologies, Inc., bioMerieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, GenapSys, Inc., Illumina, Inc., New England Biolabs, Inc., NuGEN Technologies Inc., Oxford Nanopore Technologies Limited, Pacific Biosciences of California, Inc., PerkinElmer, Inc., QIAGEN, and Thermo Fisher Scientific, among others.

The field of service providers for sequencing tests and the applications based on genome sequencing are perceived to be a lucrative business across the globe. With the impressive rise in the demand for sequencing-based diagnostics applications, namely non-invasive prenatal testing, companion diagnostics, and liquid biopsy, the service providing companies have gained popularity and acceptance across the globe. Additionally, substantial investments are being made in bioinformatics startups and service providing companies. With the growing demand for genome mapping programs, a large pool of genomic data is being generated, and the key players of the market are seeking help from the bioinformatics startups to meet the market requirement. Service providing companies help in expanding the global reach of the key players of the market and also play a significant role in increasing the adoptability of sequencing technologies across the globe.

Some of the opportunities on which significant work is being carried out presently in the market are hybridization of technologies and development of portable technologies. The best sequencer is the one with the ability to sequence long reeds, in short run time and with great accuracy. The present available sequencers on the market possess any one of the mentioned features, but not all three. In spite of the substantial investments made by prominent companies to develop the instruments with the aforementioned features, it is not expected to be the reality at any time soon. Thus, the hybridization of available technologies, such as SMRT and reversible semiconductor sequencing technology, is acknowledged to be a promising approach to cater to the needs of the market.

Table of Contents

Executive Summary

1. Market Overview

  • 1.1. The Basic NGS Workflow
  • 1.2. Historical Trends
  • 1.3. Comparative Analysis of Sanger Sequencing and Next-Generation Sequencing
  • 1.4. Global NGS Market Scenario
  • 1.5. Assumptions and Limitations

2. Market Dynamics

  • 2.1. Impact Analysis
  • 2.2. Market Drivers
    • 2.2.1. Growing Demand for Non-Invasive Diagnosis
    • 2.2.2. Technological Advancements in the Field of Computational Biology
    • 2.2.3. Growing Prominence of Precision Medicine
  • 2.3 Market Restraints
    • 2.3.1. Uncertain Reimbursement and Regulatory Policies
    • 2.3.2. Expensive Sequencing Procedures and Their Applications in Medical Treatments
    • 2.3.3. High Capital Requirement Hampering the Expansion of Global Reach
  • 2.4. Market Opportunities
    • 2.4.1. Development of Portable Technologies
    • 2.4.2. Hybridization of Technologies
    • 2.4.3. Technological Developments in the Field of Bioinformatics and Automation Software

3. Competitive Landscape

  • 3.1. Key Strategies and Developments
    • 3.1.1. Product Launch and Enhancements
    • 3.1.2. Collaborations, Partnership, Joint Ventures, and Agreements
    • 3.1.3. Mergers and Acquisition
    • 3.1.4. Business Expansion and Others
  • 3.2. Market Share Analysis (2016 and 2017)
    • 3.2.1. Market Share Analysis, by Company, by Instruments
    • 3.2.2. Market Share Analysis, by Company, by Kits and Consumables
  • 3.3. Growth Share Analysis
    • 3.3.1. Growth Share Analysis (by Products)
    • 3.3.2. Growth Share Analysis (by Sequencing Instruments Provider)
  • 3.4. Value Chain Analysis
    • 3.4.1. Value Chain Analysis of Medical Device Industry
    • 3.4.2. Value Chain Analysis: Illumina, Inc.
  • 3.5. $100 per Genome: Era of Predictive and Personalized Medicine
  • 3.6. Industry Attractiveness
    • 3.6.1. Bargaining Power of Suppliers
    • 3.6.2. Bargaining Power of Buyer
    • 3.6.3. Threat of New Entrants
    • 3.6.4. Threat of Substitute Products
    • 3.6.5. Intensity of Competitive Rivalry

4. Industry Insights

  • 4.1. Emerging Companies and Leading Investors of NGS Market
  • 4.2. Legal Requirements and Regulations
  • 4.3. Role of Service Provider in the Next-Generation Sequencing Market

5. Global NGS Market (by Product Type)

  • 5.1. Instruments
  • 5.2. Kits and Consumables
    • 5.2.1. Supply Chain of NGS Kits and Consumables
      • 5.2.1.1. Key Challenges for MedTech Supply Chain
      • 5.2.1.2. Supply Chain Model: Next-Generation Sequencing Market
      • 5.2.1.3. Thermo Fisher Scientific
      • 5.2.1.4. QIAGEN N.V.
      • 5.2.1.5. PerkinElmer, Inc.
      • 5.2.1.6. Pacific Biosciences of California, Inc.
      • 5.2.1.7. Oxford Nanopore Technologies Limited.
      • 5.2.1.8. NuGEN Technologies, Inc.
      • 5.2.1.9. New England Biolabs, Inc.
      • 5.2.1.10. Illumina, Inc.
      • 5.2.1.11. F. Hoffmann-La Roche AG
      • 5.2.1.12. Danaher Corporation
      • 5.2.1.13. ASURAGEN, INC
      • 5.2.1.14. Agilent Technologies, Inc.
      • 5.2.1.15. Adaptive Biotechnologies.
      • 5.2.1.16. 10x Genomics
  • 5.3. Software

6. Global NGS Market (by Technology)

  • 6.1. Reversible Terminator Sequencing
  • 6.2. Ion Torrent Semiconductor Sequencing
  • 6.3. Single Molecule Real Time Sequencing (SMRT)
  • 6.4. Nanopore Sequencing Technology
  • 6.5. Others

7. Global NGS Market (by Application)

  • 7.1. Pharmaceuticals
  • 7.2. Diagnostics
  • 7.3. Agricultural and Animal Research
  • 7.4. Forensics
  • 7.5. Others

8. Global NGS Market (by Region)

  • 8.1. North America
    • 8.1.1. North America: Market Dynamics
    • 8.1.2. North America NGS Market (by Product), 2018-2024
    • 8.1.3. North America NGS Market: Market Share, by Company
    • 8.1.4. North America NGS Market, (by Country)
      • 8.1.4.1. The U.S.
      • 8.1.4.2. Canada
  • 8.2. Europe
    • 8.2.1. Europe: Market Dynamics
    • 8.2.2. Europe NGS Market (by Product), 2018-2024
    • 8.2.3. Europe: Market Share, by Company
    • 8.2.4. Europe NGS Market, by Country
      • 8.2.4.1. Germany
      • 8.2.4.2. The U.K.
      • 8.2.4.3. France
      • 8.2.4.4. Italy
      • 8.2.4.5. Spain
      • 8.2.4.6. The Netherlands
      • 8.2.4.7. Sweden
      • 8.2.4.8. Denmark
      • 8.2.4.9. Rest-of-Europe
  • 8.3. Asia-Pacific
    • 8.3.1. Asia-Pacific: Market Dynamics
    • 8.3.2. Asia-Pacific NGS Market (by Product), 2018-2024
    • 8.3.3. Asia-Pacific, by Country
      • 8.3.3.1. China
      • 8.3.3.2. Japan
      • 8.3.3.3. Australia
      • 8.3.3.4. India
      • 8.3.3.5. South Korea
      • 8.3.3.6. Singapore
      • 8.3.3.7. Rest-of-the-Asia-Pacific
  • 8.4. Latin America
    • 8.4.1. Latin America: Market Dynamics
    • 8.4.2. Latin America NGS Market (by Product), 2018-2024
    • 8.4.3. Latin America: Market Share, by Company
    • 8.4.4. Latin America, by Country
      • 8.4.4.1. Brazil
      • 8.4.4.2. Mexico
      • 8.4.4.3. Rest-of-Latin America
  • 8.5. Rest-of-the-World
    • 8.5.1. Rest-of-the-World NGS Market (by Product), 2018-2024

9. Company Profiles

  • 9.1. Overview
  • 9.2. 10x Genomics
    • 9.2.1. Company Overview
    • 9.2.2. Role of 10x Genomics in the Global NGS Market
    • 9.2.3. SWOT Analysis
  • 9.3. Agilent Technologies, Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Role of Agilent Technologies, Inc. in the Global NGS Market
    • 9.3.3. Financials
      • 9.3.3.1. Key Insights about Financial Health of the Company
    • 9.3.4. SWOT Analysis
  • 9.4. Bio-Rad Laboratories, Inc
    • 9.4.1. Company Overview
    • 9.4.2. Role of Bio-Rad Laboratories, Inc. in the Global NGS Market
    • 9.4.3. Financials
      • 9.4.3.1. Key Insights about Financial Health of the Company
    • 9.4.4. SWOT Analysis
  • 9.5. BGI
    • 9.5.1. Company Overview
    • 9.5.2. Role of BGI in the Global NGS Market
    • 9.5.3. SWOT Analysis
  • 9.6. bioMerieux SA
    • 9.6.1. Company Overview
    • 9.6.2. Role of bioMerieux SA in the Global NGS Market
    • 9.6.3. Financials
      • 9.6.3.1. Key Insights about Financial Health of the Company
    • 9.6.4. SWOT Analysis
  • 9.7. Danaher Corporation
    • 9.7.1. Company Overview
    • 9.7.2. Role of Danaher Corporation in the Global NGS Market
    • 9.7.3. Financials
      • 9.7.3.1. Key Insights about Financial Health of the Company
    • 9.7.4. SWOT Analysis
  • 9.8. F. Hoffmann-La Roche AG
    • 9.8.1. Company Overview
    • 9.8.2. Role of F. Hoffmann-La Roche AG in the Global NGS Market
    • 9.8.3. Financials
      • 9.8.3.1. Key Insights about Financial Health of the Company
    • 9.8.4. SWOT Analysis
  • 9.9. Illumina, Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Role of Illumina, Inc. in the Global NGS Market
    • 9.9.3. Financials
      • 9.9.3.1. Key Insights about Financial Health of the Company
    • 9.9.4. SWOT Analysis
  • 9.10 New England Biolabs, Inc
    • 9.10.1. Company Overview
    • 9.10.2. Role of New England Biolabs, Inc. in the Global NGS Market
    • 9.10.3. SWOT Analysis
  • 9.11 NuGEN Technologies, Inc.
    • 9.11.1. Company Overview
    • 9.11.2. Role of NuGEN Technologies, Inc. in the NGS Market
    • 9.11.3. SWOT Analysis
  • 9.12 Oxford Nanopore Technologies Limited
    • 9.12.1. Company Overview
    • 9.12.2. Role of Oxford Nanopore Technologies Limited in the Global NGS Market
    • 9.12.3. SWOT Analysis
  • 9.13 Pacific Biosciences of California, Inc.
    • 9.13.1. Company Overview
    • 9.13.2. Role of Pacific Biosciences of California, Inc. in the Global NGS Market
    • 9.13.3. Financials
      • 9.13.3.1. Key Insights on the Financial Health of the Company
    • 9.13.4. SWOT Analysis
  • 9.14 QIAGEN N.V.
    • 9.14.1. Company Overview
    • 9.14.2. Role of QIAGEN N.V. in the Global NGS Market
    • 9.14.3. Financials
      • 9.14.3.1. Key Insights about Financial Health of the Company
    • 9.14.4. SWOT Analysis
  • 9.15 PerkinElmer, Inc.
    • 9.15.1. Company Overview
    • 9.15.2. Role of PerkinElmer, Inc. in the Global NGS Market
    • 9.15.3. Financials
      • 9.15.3.1. Key Insights on the Financial Health of the Company
    • 9.15.4. SWOT Analysis
  • 9.16 Thermo Fisher Scientific
    • 9.16.1. Company Overview
    • 9.16.2. Role of Thermo Fisher Scientific in the Global NGS Market
    • 9.16.3. Financials
      • 9.16.3.1. Key Insights about Financial Health of the Company
    • 9.16.4. SWOT Analysis

10. Research Scope and Methodology

  • 10.1. Report Scope
    • 10.1.1. Global Next-Generation Sequencing Market: Research Methodology
    • 10.1.2. Primary Data Sources
    • 10.1.3. Secondary Data Sources
    • 10.1.4. Data Triangulation
    • 10.1.5. Assumptions and Limitations
    • 10.1.6. Data and Prediction Modelling

11. Annexures

  • 11.1. Annexure I : Key Developments and Strategies (January 2014 to February 2019)
  • 11.2. Annexure II : Product Mapping

List of Tables

  • Table 1.1: Sanger Sequencing vs. Next-Generation Sequencing
  • Table 2.1: Impact Analysis
  • Table 4.1: Funding Scenario
  • Table 4.2: Regulatory Bodies
  • Table 4.3: Country-Wise Service Providers
  • Table 5.1: Global NGS Instruments Market (by Type), 2018-2024, $Million
  • Table 5.2: Global NGS Kits and Consumables Market (by Type), 2018-2024, $Million
  • Table 5.3: Few Suppliers of Thermo Fisher Scientific
  • Table 5.4: Few Suppliers of QIAGEN N.V.
  • Table 5.5: Few Suppliers of PerkinElmer, Inc.
  • Table 5.6: Few Suppliers of Pacific Biosciences of California, Inc.
  • Table 5.7: Few Suppliers of Oxford Nanopore Technologies Limited.
  • Table 5.8: Few Suppliers of NuGEN Technologies, Inc.
  • Table 5.9: Few Suppliers of New England Biolabs.
  • Table 5.10: Key Offerings of Illumina, Inc.
  • Table 5.11: Few Suppliers of Illumina, Inc.
  • Table 5.12: Few Suppliers of F. Hoffmann-La Roche AG
  • Table 5.13: Few Suppliers of Danaher Corporation
  • Table 5.14: Few Suppliers of ASURAGEN, INC.
  • Table 5.15: Few Suppliers of Agilent Technologies, Inc.
  • Table 5.16: Few Suppliers of Adaptive Biotechnologies.
  • Table 5.17: Few Suppliers of 10x Genomics
  • Table 6.1: Reversible Terminator Sequencing Country Wise Service Providers
  • Table 6.2: Ion Torrent Semiconductor Sequencing Country Wise Service Providers
  • Table 6.3: Single Molecule Real-Time Sequencing Country Wise Service Providers
  • Table 8.1: North America Next-Generation Sequencing Market (by Product), 2018-2024, $Million
  • Table 8.2: Europe Next-Generation Sequencing Market Revenue (by Product), 2018-2024, $Million
  • Table 8.3: Asia-Pacific Next-Generation Sequencing Market Revenue (by Product), 2018-2024, $Million
  • Table 8.4: Latin America Next-Generation Sequencing Market Revenue (by Product), 2018-2024, $Million
  • Table 8.5: Rest-of-the-World: Next-Generation Sequencing Market Revenue (by Product), 2018-2024, $Million

List of Figures

  • Figure 1: Drivers and Restraints of Next-Generation Sequencing Market
  • Figure 2: Key Strategies Incorporated by Stakeholders of NGS Market, to Sustain the Compatation (from January 2014 to February 2019)
  • Figure 3: Leading Service Providers in the Next-Generation Sequencing Market
  • Figure 4: Global Next-Generation Sequencing Market, 2018-2024
  • Figure 5: Global Next-Generation Sequencing Market Share (by Product), 2018 and 2024
  • Figure 6: Global Next-Generation Sequencing Market Share (by Technology), 2018 and 2024
  • Figure 7: Global Next-Generation Sequencing Market Share (by Application), 2018 and 2024
  • Figure 8: Global Next-Generation Sequencing Market Share (by Region), 2018 and 2024
  • Figure 1.1: Different steps in Next-Generation Sequencing Technology
  • Figure 1.2: Evolution of Next-Generation Sequencers with Progress in Molecular Technologies
  • Figure 1.3: Global Next-Generation Sequencing Market, 2018-2024
  • Figure 2.1: Market Dynamics of Global NGS Market
  • Figure 3.1: Competitive Landscape, January 2014-February 2019
  • Figure 3.2: Share of Key Developments and Strategies, January 2014-February 2019
  • Figure 3.3: Product Launch and Enhancements Share (by Companies), January 2014-February 2019
  • Figure 3.4: Collaborations, Partnership, Joint Ventures, and Agreements Share (by Companies), January 2014-February 2019
  • Figure 3.5: Mergers and Acquisitions Share (by Companies), January 2014-February 2019
  • Figure 3.6: Business Expansion and Others Share (by Companies), January 2014-February 2019
  • Figure 3.7: Market Share Analysis (by Companies) for the Global Next-Generation Sequencing Market, 2016 and 2017
  • Figure 3.8: Market Share Analysis (by Companies) for the Global Next-Generation Sequencing Instruments Market, 2016 and 2017
  • Figure 3.9: Market Share Analysis (by Companies) for the Global Next-Generation Sequencing Kits and Consumables Market, 2016 and 2017
  • Figure 3.10: Growth Share Matrix for Global Next-Generation Sequencing Market (by Products), 2017
  • Figure 3.11: Growth Share Matrix for Global Next-Generation Sequencing Market (by Sequencing Instruments Provider), 2017
  • Figure 3.12: Key Entities of Value Chain
  • Figure 3.13: Value Chain of Medical Device Industry
  • Figure 3.14: Value Chain Analysis: Illumina, Inc.
  • Figure 3.15: Cost Per Genome Sequencing ($) vs. Maximum Output of Sequencer Per Run
  • Figure 3.16: Maximum Output per Run Required for $100 Genome Sequencing
  • Figure 4.1: Level of NGS Service Providers Presence
  • Figure 5.1: Global NGS Market (by Product Type)
  • Figure 5.2: Global NGS Market (by Product Type), 2018 and 2024
  • Figure 5.3: Pivotal Types of Instruments Associated with NGS
  • Figure 5.4: Global NGS Instruments Market, 2018-2024
  • Figure 5.5: Pivotal Types of Kits & Consumables Associated with NGS
  • Figure 5.6: Global NGS Kits & Consumables Market, 2018-2024
  • Figure 5.7: Key Entities of Supply Chain
  • Figure 5.8: Comparison of MedTech Industry and Total Consumer Industry Supply Chain
  • Figure 5.9: Supply Chain Model
  • Figure 5.10: Different Types of Computational Platforms
  • Figure 5.11: Global NGS Software Market, 2018-2024
  • Figure 6.1: Different Types of Sequencing
  • Figure 6.2: Global NGS Market (by Technology), 2018 and 2024
  • Figure 6.3: Global NGS Market for Reversible Terminator Sequencing, 2018-2024
  • Figure 6.4: Global NGS Market for Ion Torrent Semiconductor Sequencing, 2018-2024
  • Figure 6.5: Global NGS Market for Single Molecule Real-Time Sequencing, 2018-2024
  • Figure 6.6: Global NGS Market for Nanopore Sequencing Technology, 2018-2024
  • Figure 6.7: Global NGS Market for Other Technologies, 2018-2024
  • Figure 7.1: Leading Fields Which are Witnessing Colossal Incorporation of NGS
  • Figure 7.2: Global NGS Market (by Application), 2018-2024
  • Figure 7.3: Application of NGS in the field of Pharmaceuticals
  • Figure 7.4: Global NGS Market for Pharmaceuticals Applications, 2018-2024
  • Figure 7.5: Applications of NGS in the field of Diagnostics
  • Figure 7.6: Global NGS Market for Diagnostics Applications, 2018-2024
  • Figure 7.7: Global NGS Market for Agricultural and Animal Research Applications, 2018-2024
  • Figure 7.7: Global NGS Market for Forensics Applications, 2018-2024
  • Figure 7.8: Global NGS Market for Other Applications, 2018-2024
  • Figure 8.1: Global Next-Generation Sequencing Market (by Region), 2018 and 2024
  • Figure 8.2: North America: Next-Generation Sequencing Market, (2018-2024)
  • Figure 8.3: North America: Market Dynamics
  • Figure 8.4: Market Share Analysis: North America Sequencing Market, 2016 and 2017
  • Figure 8.5: North America: Next-Generation Sequencing Market (by Country), 2018 and 2024
  • Figure 8.6: The U.S.: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.7: Canada.: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.8: Europe: Next-Generation Sequencing Market, (2018-2024)
  • Figure 8.9: Europe: Market Dynamics
  • Figure 8.10: Market Share Analysis: Europe Sequencing Market, 2016 and 2017
  • Figure 8.11: Europe: Next-Generation Sequencing Market (by Country), 2018 and 2024
  • Figure 8.12: Germany: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.13: The U.K.: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.14: France: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.15: Italy: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.16: Spain: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.17: The Netherlands: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.18: Sweden: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.19: Denmark: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.20: Rest-of-Europe: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.21: Asia-Pacific: Next-Generation Sequencing Market, (2018-2024)
  • Figure 8.22: Asia-Pacific: Market Dynamics
  • Figure 8.23: Market Share Analysis: Asia-Pacific Sequencing Market, 2016 and 2017
  • Figure 8.24: Asia-Pacific: Next-Generation Sequencing Market (by Country), 2018 and 2024
  • Figure 8.25: China: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.26: Japan: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.27: Australia: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.28: India: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.29: South Korea: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.30: Singapore: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.31: Rest-of-the-Asia-Pacific: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.32: Latin America: Next-Generation Sequencing Market, (2018-2024)
  • Figure 8.33: Latin America: Market Dynamics
  • Figure 8.34: Market Share Analysis: Latin America Sequencing Market, 2016 and 2017
  • Figure 8.35: Latin America: Next-Generation Sequencing Market (by Country), 2018 and 2024
  • Figure 8.36: Brazil: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.37: Mexico: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.38: Rest-of-Latin America: Next-Generation Sequencing Market, 2018-2024
  • Figure 8.39: Rest-of-the-World: Next-Generation Sequencing Market, 2018-2024
  • Figure 9.1: Shares of Key Company Profiles
  • Figure 9.2: 10x Genomics Product Offerings for Global Next-Generation Sequencing Market
  • Figure 9.3: 10X Genomics: SWOT Analysis
  • Figure 9.4: Agilent Technologies, Inc. Product Offerings for Global Next-Generation Sequencing Market
  • Figure 9.5: Agilent Technologies, Inc.: Overall Financials, 2016-2018
  • Figure 9.6: Agilent Technologies, Inc.: Revenue (by Segment), 2016-2018
  • Figure 9.7: Agilent Technologies, Inc.: Revenue (by Region), 2016-2018
  • Figure 9.8: Agilent Technologies, Inc.: R&D Expenditure, 2016-2018
  • Figure 9.9: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 9.10: Bio-Rad Laboratories, Inc. Product Offerings for Global Next-Generation Sequencing Market
  • Figure 9.11: Bio-Rad Laboratories, Inc.: Overall Financials, 2015-2017
  • Figure 9.12: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2015-2017
  • Figure 9.13: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2015-2017
  • Figure 9.14: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2015-2017
  • Figure 9.15: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 9.16: BGI Product Offerings for Global Next-Generation Sequencing Market
  • Figure 9.17: BGI : SWOT Analysis
  • Figure 9.18: bioMerieux SA Product Offerings for Global Next-Generation Sequencing Market
  • Figure 9.19: bioMerieux S.A.: Overall Financials, 2015-2017
  • Figure 9.20: bioMerieux S.A.: Revenue (by Segment), 2015-2017
  • Figure 9.21: bioMerieux S.A.: Revenue (by Region), 2015-2017
  • Figure 9.22: bioMerieux S.A.: R&D Expenditure, 2015-2017
  • Figure 9.23: bioMerieux SA.: SWOT Analysis
  • Figure 9.24: Danaher Corporation Product Offerings for Global Next-Generation Sequencing Market
  • Figure 9.25: Danaher Corporation: Overall Financials, 2015-2017
  • Figure 9.26: Danaher Corporation: Revenue (by Segment), 2015-2017
  • Figure 9.27: Danaher Corporation: Revenue (by Region), 2015-2017
  • Figure 9.28: Danaher Corporation: R&D Expenditure, 2015-2017
  • Figure 9.29: Danaher Corporation: SWOT Analysis
  • Figure 9.30: F. Hoffmann-La Roche AG Product Offerings for Global Next-Generation Sequencing Market
  • Figure 9.31: F. Hoffmann-La Roche AG: Overall Financials, 2016-2018
  • Figure 9.32: F. Hoffmann-La Roche AG: Revenue (by Segment), 2016-2018
  • Figure 9.33: F. Hoffmann-La Roche AG: Revenue (by Region), 2016-2018
  • Figure 9.34: F. Hoffmann-La Roche AG: R&D Expenditure, 2016-2018
  • Figure 9.35: F. Hoffmann-La Roche AG: SWOT Analysis
  • Figure 9.36: Illumina, Inc. Product Offerings for Global Next-Generation Sequencing Market
  • Figure 9.37: Illumina, Inc.: Overall Financials, 2016-2018
  • Figure 9.38: Illumina, Inc.: Revenue (by Segment), 2016-2018
  • Figure 9.39: Illumina, Inc.: Revenue (by Region), 2016-2018
  • Figure 9.40: Illumina, Inc.: R&D Expenditure, 2016-2018
  • Figure 9.41: Illumina, Inc.: SWOT Analysis
  • Figure 9.42: New England Biolabs, Inc Product Offerings for Global Next-Generation Sequencing Market
  • Figure 9.43: New England Biolabs, Inc.: SWOT Analysis
  • Figure 9.44: NuGEN Technologies, Inc Product Offerings for Global Next-Generation Sequencing Market
  • Figure 9.45: NuGEN Technologies, Inc.: SWOT Analysis
  • Figure 9.46: Oxford Nanopore Technologies Limited Product Offerings for Global Next-Generation Sequencing Market
  • Figure 9.47: Oxford Nanopore Technologies Limited : SWOT Analysis
  • Figure 9.48: Pacific Biosciences of California, Inc. Product Offerings for Global Next-Generation Sequencing Market
  • Figure 9.49: Pacific Biosciences of California, Inc.: Overall Financials, 2015-2017
  • Figure 9.50: Pacific Biosciences of California, Inc.: Net Revenue by Region, 2015-2017
  • Figure 9.51: Pacific Biosciences of California, Inc.:R&D Expenditure 2015-2017
  • Figure 9.52: Pacific Biosciences of California, Inc.: SWOT Analysis
  • Figure 9.53: QIAGEN N.V.: Overall Product Portfolio
  • Figure 9.54: QIAGEN N.V.: Overall Financials, 2015-2017
  • Figure 9.55: QIAGEN N.V.: Revenue (by Segment), 2015-2017
  • Figure 9.56: QIAGEN N.V.: Revenue (by Region), 2015-2017
  • Figure 9.57: QIAGEN N.V.: R&D Expenditure, 2015-2017
  • Figure 9.58: QIAGEN N.V.: SWOT Analysis
  • Figure 9.59: PerkinElmer, Inc. Product Offerings for Global Next-Generation Sequencing Market
  • Figure 9.60: PerkinElmer, Inc.: Overall Financials, 2015-2017
  • Figure 9.61: PerkinElmer, Inc.: Net Revenue (by Segment), 2015-2017
  • Figure 9.62: PerkinElmer, Inc.: Net Revenue (By Region), 2015-2017
  • Figure 9.63: PerkinElmer, Inc.: Net Revenue (By Region), 2016-2018
  • Figure 9.64: PerkinElmer, Inc.: SWOT Analysis
  • Figure 9.65: Thermo Fisher Scientific: Overall Product Portfolio (NGS Market)
  • Figure 9.66: Thermo Fisher Scientific: Overall Financials, 2015-2017
  • Figure 9.67: Thermo Fisher Scientific: Revenue (by Segment), 2015-2017
  • Figure 9.68: Thermo Fisher Scientific: Revenue (by Region), 2015-2017
  • Figure 9.69: Thermo Fisher Scientific: R&D Expenditure, 2015-2017
  • Figure 9.70: Thermo Fisher Scientific: SWOT Analysis
  • Figure 10.1: Next-Generation Sequencing: Market Segmentation
  • Figure 10.2: Next-Generation Sequencing Market Segmentation
  • Figure 10.3: Primary Research
  • Figure 10.4: Secondary Research
  • Figure 10.5: Data Triangulation
  • Figure 10.6: Top-down Approach (Segment-wise Analysis)
  • Figure 10.7: Bottom-up Approach (Segment-wise Analysis)
  • Figure 10.8: Assumptions and Limitations
  • Figure 10.9: Considered Factors for Data Prediction and Modelling